《中国康复理论与实践》

中国康复理论与实践 >

2019 , Vol. 25 >Issue 3: 352 - 356

DOI: https://doi.org/10.3969/j.issn.1006-9771.2019.03.019

临床研究

帕金森病患者的血脂水平及其相关性

  • 于鸿远 ,
  • 何景华 ,
  • 刘双 ,
  • 孙丽娟 ,
  • 殷雁
展开
  • 大连医科大学附属第二医院神经内科，辽宁大连市 116027
于鸿远(1992-)，女，汉族，吉林通化市人，硕士研究生，主要研究方向：帕金森病。

收稿日期: 2018-12-06

  修回日期: 2019-01-21

  网络出版日期: 2019-04-02

基金资助

1.国家自然科学基金青年基金项目(No. 81801173)；2.辽宁省自然科学基金面上项目(No. 20180550891)

收起

Relationship between Serum Lipid Levels and Parkinson's Disease

  • YU Hong-yuan ,
  • HE Jing-hua ,
  • LIU Shuang ,
  • SUN Li-juan ,
  • YIN Yan
Expand
  • Neurology Department, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027, China

Received date: 2018-12-06

  Revised date: 2019-01-21

  Online published: 2019-04-02

Supported by

National Natural Science Foundation of China (Youth) (No. 81801173) and Liaoning Natural Science Foundation (General) (No. 20180550891)

Fold

摘要

目的 探究血脂与帕金森病的关系以及对帕金森病的预测价值。方法 2016年1月至2018年11月，帕金森病患者145例为患者组，同期122例健康体检者为对照组，检测血脂水平，分析各项血脂指标与帕金森病病程、疾病严重程度和运动分型的相关性，计算相关血脂指标的预测值。结果 患者组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1 (ApoA1)、载脂蛋白B (ApoB)均低于对照组(t > 2.089, P < 0.05)；Logistic回归分析显示，ApoA1是患帕金森病的保护因素(OR = 0.081, P < 0.01)。ApoA1的最佳截取阈值为1.38 mmol/L，敏感度性0.72，特异性0.68。结论 帕金森病患者总体血脂水平低于健康人，低ApoA1可能是帕金森病发病的潜在独立危险因素，可以作为预测帕金森病患病风险的参考。

关键词： 帕金森病; 血脂; 载脂蛋白A1; 相关性

本文引用格式

于鸿远 , 何景华 , 刘双 , 孙丽娟 , 殷雁 . 帕金森病患者的血脂水平及其相关性[J]. 中国康复理论与实践, 2019 , 25(3) : 352 -356 . DOI: 10.3969/j.issn.1006-9771.2019.03.019

Abstract

Objective To investigate the relationship between serum lipids and Parkinson's disease, and its predictive value for Parkinson's disease. Methods From January, 2016 to November, 2018, 145 patients with Parkinson's disease and other 122 healthy subjects were selected. They were measured the various lipid indexes. Results Total cholesterol, low density lipoprotein cholesterol, Apolipoprotein A1 (ApoA1) and Apolipoprotein B (ApoB) were less in the patients than in the controls (t > 2.089, P < 0.05). ApoA1 was an independent protective factor from Logistic regression (OR = 0.081, P < 0.01). The most optimal cut-off threshold of ApoA1 was 1.38 mmol/L, with the sensitivity of 0.72 and the specificity of 0.68. Conclusion The lipid decreased in patients with Parkinson's disease. Low ApoA1 may be a potential independent risk factor for Parkinson's disease, which may be a predictor for it.

Key words： Parkinson's disease; serum lipids; apolipoprotein A1; correlation

参考文献

1 ZhangT, YuS, GuoP, et al. Nonmotor symptoms in patients with Parkinson disease: a cross-sectional observational study [J]. Medicine, 2016, 95(50): e5400.
2 黄星会,霍丽涛,吴庆文,等. 帕金森病的非运动症状及研究进展[J]. 中国康复理论与实践, 2013, 19(11): 1013-1015.
3 王刚,崔海伦,刘军,等. 帕金森病发病机制及诊断与治疗转化研究进展[J]. 中国现代神经疾病杂志, 2018, 18(1): 19-24.
4 RizekP, KumarN, JogMS. An update on the diagnosis and treatment of Parkinson disease [J]. CMAJ, 2016, 188(16): 1157-1165.
5 HuangX, AbbottR D, PetrovitchH, et al. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study [J]. Mov Disord, 2010, 23(7): 1013-1018.
6 SimonK C, ChenH, SchwarzschildM, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease [J]. Neurology, 2007, 69(17): 1688-1695.
7 de LauL M, KoudstaalP J, HofmanA, et al. Serum cholesterol levels and the risk of Parkinson's disease [J]. Am J Epidemiol, 2006, 164(10): 998-1002.
8 GuoX, SongW, ChenK, et al. The serum lipid profile of Parkinson's disease patients: a study from China [J]. Int J Neurosci, 2015, 125(11): 838-844.
9 EmamzadehF N, SurguchovA. Parkinson's disease: biomarkers, treatment, and risk factors [J]. Front Neurosci, 2018, 12: 612.
10 PaulR, ChoudhuryA, KumarS, et al. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: involvement of mitochondrial dysfunctions and oxidative stress [J]. PLoS One, 2017, 12(2): e0171285.
11 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4): 268-271.
12 SchragA, JahanshahiM, QuinnN. What contributes to quality of life in patients with Parkinson's disease? [J]. J Neurol Neurosurg Psychiatry, 2000, 69(3): 308-312.
13 HoehnM M, YahrM D. Parkinsonism: onset, progression and mortality [J]. Neurology, 2001, 57(3): 11-26.
14 VanceJ E. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases [J]. Dis Model Mech, 2012, 5(6): 746-755.
15 LiL, LiuM S, LiG Q, et al. Relationship between apolipoprotein superfamily and Parkinson's disease [J]. Chin Med J (Engl), 2017, 130(21): 2616-2623.
16 QiangJ K, WongY C, SiderowfA, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease [J]. Ann Neurol, 2013, 74(1): 119-127.
17 WangE S, SunY, GuoJ G, et al. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease [J]. Acta Neurol Scand, 2010, 122(5): 350-359.
18 GaoX, SimonK C, SchwarzschildM A, et al. Prospective study of statin use and risk of Parkinson disease [J]. Arch Neurol, 2012, 69(3): 380-384.
19 LeeY C, LinC H, WuR M, et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study [J]. Neurology, 2013, 81(5): 410-416.
20 SwansonC R, LiK, UngerT L, et al. Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype [J]. Mov Disord, 2015, 30(6): 805-812.
21 LewisT L, CaoD, LuH, et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease [J]. J Biol Chem, 2010, 285(47): 36958-36968.
22 ArenasF, Garcia-RuizC, Fernandez-ChecaJ C. Intracellular cholesterol trafficking and impact in neurodegeneration [J]. Front Mol Neurosci, 2017, 10: 382.
23 LimL, Jackson-LewisV, WongL C, et al. Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease [J]. Cell Death Differ, 2012, 19(3): 416-427.
24 HuangX, AuingerP, EberlyS, et al. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP [J]. PLoS One, 2011, 6(8): e22854.
25 BennM, NordestgaardB G, Frikke-SchmidtR, et al. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study [J]. BMJ, 2017, 357: j1648.
26 LuoL, YuanX, HuangW, et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis [J]. Intern Med J, 2015, 45(5): 546-557.
27 ZhangL, WangX, WangM, et al. Circulating cholesterol levels may link to the factors influencing Parkinson's risk [J]. Front Neurol, 2017, 8: 501.
28 van der MarkM, NijssenP C, VlaanderenJ, et al. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking [J]. PLoS One, 2014, 9(4): e95297.
29 ChenH, HuangX, GuoX, et al. Smoking duration, intensity, and risk of Parkinson disease [J]. Neurology, 2010, 74(11): 878-884.
30 RitzB, LeeP C, LassenC F, et al. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease [J]. Neurology, 2014, 83(16): 1396-1402.
Options
文章导航

/

〈 〉